A 52-week, international, multi-center, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100 mg od [once daily], lumiracoxib 100 mg bid [twice daily] and celecoxib 200 mg od in patients with primary osteoarthritis of hip, knee, hand or spine

Trial Profile

A 52-week, international, multi-center, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100 mg od [once daily], lumiracoxib 100 mg bid [twice daily] and celecoxib 200 mg od in patients with primary osteoarthritis of hip, knee, hand or spine

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2012

At a glance

  • Drugs Celecoxib; Lumiracoxib
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 18 May 2012 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top